Comparison · NCT00072462-38743f23
Anastrozole vs Tamoxifen: Number of Participants With ER- Breast Cancer Recurrence
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Anastrozole vs Tamoxifen: Number of Participants With ER- Breast Cancer Recurrence. Trial comparisons, record NCT00072462-38743f23. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00072462-38743f23
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0166 | 0.0112 | 0.0245 | wilson | |
| Risk in group 2 | 0.0101 | 0.00611 | 0.0166 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00649 | -0.00195 | 0.0154 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.64 | 0.866 | 3.12 | log | |
| Odds ratio, group 1 over group 2 | 1.66 | 0.865 | 3.17 | log | |
| Number needed to treat, for one more participant with the outcome on Anastrozole than on Tamoxifen | 154 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Anastrozole | Anastrozole: Anastrozole 1mg + Tamoxifen placebo | 24 | 1,449 | OG000 |
| Group 2 | Tamoxifen | tamoxifen citrate: Tamoxifen 20mg + Anastrozole placebo | 15 | 1,489 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With ER- Breast Cancer Recurrence
- Description
- Time frame
Date of the breast cancer occurrence is defined as the date of the confirmation of the specific event (from randomisation to date of occurrence). Data presented is from randomisation to study completion, median follow-up was 11.6 years (IQR: 9.9-13.5).
- Population
Source ClinicalTrials.gov
Trial
- Title
- Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
- NCT number
- NCT00072462
- Phases
- PHASE3
- Conditions
- Breast Cancer
- Interventions
- tamoxifen citrate, Anastrozole
- Lead sponsor
- Queen Mary University of London
- Results first posted
- 2024-09-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00072462?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00072462-38743f23